TW432073B
(en)
*
|
1995-12-28 |
2001-05-01 |
Pfizer |
Pyrazolopyridine compounds
|
HN1996000101A
(es)
*
|
1996-02-28 |
1997-06-26 |
Inc Pfizer |
Terapia combinada para la osteoporosis
|
CA2283564C
(en)
|
1997-04-15 |
2007-07-10 |
Csir |
Pharmaceutical compositions having appetite suppressant activity
|
GB2324726A
(en)
*
|
1997-05-01 |
1998-11-04 |
Merck & Co Inc |
Combination Therapy for the Treatment of Osteoporosis
|
EP1001970B1
(en)
|
1997-06-25 |
2007-03-07 |
Pfizer Inc. |
Dipeptide derivatives as growth hormone secretagogues
|
UA53716C2
(uk)
*
|
1997-06-25 |
2003-02-17 |
Пфайзер Продактс Інк. |
Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
|
UA64751C2
(uk)
*
|
1997-06-25 |
2004-03-15 |
Пфайзер Продактс Інк. |
Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
|
ZA987383B
(en)
*
|
1997-08-19 |
2000-02-17 |
Lilly Co Eli |
Treatment of congestive heart failure with growth hormone secretagogues.
|
US6329342B1
(en)
|
1997-08-19 |
2001-12-11 |
Eli Lilly And Company |
Treatment of congestive heart failure with growth hormone secretagogues
|
US6893877B2
(en)
*
|
1998-01-12 |
2005-05-17 |
Massachusetts Institute Of Technology |
Methods for screening substances in a microwell array
|
PL341707A1
(en)
|
1998-01-16 |
2001-04-23 |
Novo Nordisk As |
Compounds exibiting growth hormone releasing properties
|
US6657063B1
(en)
*
|
1998-04-30 |
2003-12-02 |
Pfizer Inc. |
Combinations of β3 agonists and growth hormone secretagogues
|
EP1084109B1
(en)
*
|
1998-06-03 |
2005-01-26 |
Pfizer Products Inc. |
2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
|
ZA993975B
(en)
*
|
1998-06-16 |
2000-12-15 |
Pfizer Prod Inc |
Combination therapy for musculoskeletal frailty.
|
BR9911357A
(pt)
*
|
1998-06-16 |
2001-03-13 |
Pfizer Producs Inc |
Combinações terapêuticas de moduladores (seletivos) de receptor de estrogênio (serm) e secretagogos de hormÈnio de crescimento (ghs) para tratar fragilidade músculo-esqueletal
|
PA8471201A1
(es)
*
|
1998-06-16 |
2000-09-29 |
Pfizer Prod Inc |
Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
|
US6639076B1
(en)
|
1998-08-18 |
2003-10-28 |
Eli Lilly And Company |
Growth hormone secretagogues
|
US6358951B1
(en)
*
|
1998-08-21 |
2002-03-19 |
Pfizer Inc. |
Growth hormone secretagogues
|
EP1156808A2
(en)
*
|
1998-09-02 |
2001-11-28 |
Merck & Co., Inc. |
Enhancement of return to independent living status with a growth hormone secretagogue
|
DK1112095T3
(da)
|
1998-09-11 |
2003-03-17 |
Michael Dr Raschke |
Biologisk aktive implantater
|
US6337332B1
(en)
|
1998-09-17 |
2002-01-08 |
Pfizer Inc. |
Neuropeptide Y receptor antagonists
|
US6380184B1
(en)
|
1998-10-28 |
2002-04-30 |
Bristol-Myers Squibb Co. |
Benzoazepines and analogs thereof useful as growth hormone secretagogues
|
US6194578B1
(en)
*
|
1998-11-20 |
2001-02-27 |
Pfizer Inc. |
Dipeptide derivatives
|
US6297380B1
(en)
*
|
1998-11-23 |
2001-10-02 |
Pfizer Inc. |
Process and intermediates for growth hormone secretagogues
|
SI1004583T1
(en)
*
|
1998-11-23 |
2004-12-31 |
Pfizer Products Inc. |
Process and hydantoin intermediates for the synthesis of growth hormone secretagogues
|
EP1158996A4
(en)
|
1999-02-18 |
2005-01-12 |
Kaken Pharma Co Ltd |
NEW AMID DERIVATIVES AS GROWTH HORMONE SECRETION CONVEYORS
|
US6828331B1
(en)
|
1999-02-19 |
2004-12-07 |
Eli Lilly And Company |
Growth hormone secretagogues
|
US6541634B2
(en)
|
1999-02-26 |
2003-04-01 |
Pfizer Inc. |
Process for preparing growth hormone secretagogues
|
US6525203B1
(en)
|
1999-03-12 |
2003-02-25 |
Bristol-Myers Squibb Company |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
US6518292B1
(en)
|
1999-03-12 |
2003-02-11 |
Bristol-Myers Squibb Co. |
Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
|
AU772752B2
(en)
|
1999-07-26 |
2004-05-06 |
Baylor College Of Medicine |
Super-active porcine growth hormone releasing hormone analog
|
GB2355657B
(en)
|
1999-10-27 |
2004-07-28 |
Phytopharm Plc |
Inhibitors Of Gastric Acid Secretion
|
EP1113007A1
(en)
*
|
1999-12-24 |
2001-07-04 |
Pfizer Inc. |
Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
|
WO2001047558A1
(fr)
*
|
1999-12-28 |
2001-07-05 |
Kaken Pharmaceutical Co., Ltd. |
Medicaments protegeant les nerfs
|
CA2400644C
(en)
*
|
2000-02-18 |
2009-07-14 |
Board Of Trustees Of The Leland Stanford Junior University |
Apparatus and methods for parallel processing of micro-volume liquid reactions
|
US20020151040A1
(en)
|
2000-02-18 |
2002-10-17 |
Matthew O' Keefe |
Apparatus and methods for parallel processing of microvolume liquid reactions
|
EP1132388A3
(en)
|
2000-03-09 |
2004-03-03 |
Pfizer Products Inc. |
Hexahydropyrazolo[4,3-c]pyridine metabolites
|
EP1149583A3
(en)
*
|
2000-04-13 |
2001-11-14 |
Pfizer Products Inc. |
Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
|
CA2408486A1
(en)
|
2000-05-11 |
2001-11-15 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
|
DOP2001000154A
(es)
*
|
2000-05-25 |
2002-05-15 |
Pfizer Prod Inc |
Combinación de secretagogos de hormona del crecimiento y antidepresivos
|
CA2410597A1
(en)
|
2000-05-30 |
2001-12-06 |
Merck & Co., Inc. |
Melanocortin receptor agonists
|
EP1159964B1
(en)
|
2000-05-31 |
2009-10-28 |
Pfizer Products Inc. |
Use of growth hormone secretagogues for stimulating gastrointestinal motility
|
IL143690A0
(en)
*
|
2000-06-19 |
2002-04-21 |
Pfizer Prod Inc |
The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
|
EP1181933A3
(en)
*
|
2000-06-29 |
2002-04-10 |
Pfizer Products Inc. |
Use of growth hormone secretagogues for stimulating or increasing appetite
|
IL143942A0
(en)
*
|
2000-06-29 |
2002-04-21 |
Pfizer Prod Inc |
Use of growth hormone secretagogues for treatment of physical performance decline
|
GB2363985B
(en)
|
2000-06-30 |
2004-09-29 |
Phytopharm Plc |
Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
|
IL144468A0
(en)
*
|
2000-07-27 |
2002-05-23 |
Pfizer Prod Inc |
Use of growth hormone secretagogues for improvement of functional health status
|
BR0113626A
(pt)
*
|
2000-08-30 |
2003-06-17 |
Pfizer Prod Inc |
Formulações de liberação sustentada para secretores de hormÈnio do crescimento
|
IL145106A0
(en)
*
|
2000-08-30 |
2002-06-30 |
Pfizer Prod Inc |
Intermittent administration of a geowth hormone secretagogue
|
EP1192943A3
(en)
*
|
2000-09-28 |
2002-11-27 |
Pfizer Products Inc. |
Use of growth hormone secretagogues in conjunction with physical exercise
|
JP4361271B2
(ja)
*
|
2000-10-10 |
2009-11-11 |
バイオトローブ・インコーポレイテツド |
アッセイ、合成、および保存用の器具、ならびに、その作製、使用、および操作の方法
|
US20100261159A1
(en)
|
2000-10-10 |
2010-10-14 |
Robert Hess |
Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
|
CA2347330C
(en)
*
|
2001-05-10 |
2002-03-12 |
Pharmaceutical Partners Of Canada Inc. |
Liquid injectable formulation of disodium pamidronate
|
US7125840B2
(en)
|
2001-10-09 |
2006-10-24 |
Eli Lilly And Company |
Substituted dipeptides as growth hormone secretagogues
|
AU2002357692A1
(en)
|
2001-11-09 |
2003-05-26 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
|
US20030199514A1
(en)
*
|
2002-03-27 |
2003-10-23 |
Fryburg David A. |
Methods for improving efficacy of treatment with growth hormone secretagogues
|
AU2003220441A1
(en)
|
2002-04-09 |
2003-10-27 |
Eli Lilly And Company |
Dipeptidic growth hormone secretagogues
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
US8277753B2
(en)
|
2002-08-23 |
2012-10-02 |
Life Technologies Corporation |
Microfluidic transfer pin
|
EP1539959A2
(en)
*
|
2002-09-18 |
2005-06-15 |
Centre Hospitalier de l'Université de Montréal (CHUM) |
Ghrh analogues
|
US20060094108A1
(en)
*
|
2002-12-20 |
2006-05-04 |
Karl Yoder |
Thermal cycler for microfluidic array assays
|
WO2004074818A2
(en)
*
|
2002-12-20 |
2004-09-02 |
Biotrove, Inc. |
Assay apparatus and method using microfluidic arrays
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
WO2004108120A1
(en)
*
|
2003-06-11 |
2004-12-16 |
Pfizer Products Inc. |
Use of growth hormone secretagogues for treatment of fibromyalgia
|
US7476653B2
(en)
|
2003-06-18 |
2009-01-13 |
Tranzyme Pharma, Inc. |
Macrocyclic modulators of the ghrelin receptor
|
WO2005027913A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Pfizer Products Inc. |
Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
|
WO2005028438A1
(ja)
|
2003-09-22 |
2005-03-31 |
Banyu Pharmaceutical Co., Ltd. |
新規ピペリジン誘導体
|
US7129561B2
(en)
*
|
2003-11-19 |
2006-10-31 |
International Business Machines Corporation |
Tri-metal and dual-metal stacked inductors
|
US8105554B2
(en)
|
2004-03-12 |
2012-01-31 |
Life Technologies Corporation |
Nanoliter array loading
|
EP1789409A4
(en)
*
|
2004-04-02 |
2010-09-08 |
Elixir Pharmaceuticals Inc |
SULPHONAMIDES AND ITS USES
|
EP2305352A1
(en)
|
2004-04-02 |
2011-04-06 |
Merck Sharp & Dohme Corp. |
5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
|
WO2005097174A2
(en)
*
|
2004-04-07 |
2005-10-20 |
Gastrotech Pharma A/S |
Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
|
AR053407A1
(es)
|
2004-07-28 |
2007-05-09 |
Glaxo Group Ltd |
Derivados de piperazina, proceso para la preparacion de dicho compuesto y composicion farmaceutica que lo comprende.
|
US20060105453A1
(en)
|
2004-09-09 |
2006-05-18 |
Brenan Colin J |
Coating process for microfluidic sample arrays
|
KR101380200B1
(ko)
*
|
2004-08-12 |
2014-04-01 |
헬신 세라퓨틱스 (유.에스.) 인크. |
성장 호르몬 분비촉진제를 이용하여 위장관계의 운동성을촉진하는 방법
|
EP1781311A4
(en)
|
2004-08-18 |
2010-02-17 |
Elixir Pharmaceuticals Inc |
WACHSTUMSHORMONSEKRETAGOGE
|
JP5154927B2
(ja)
|
2005-05-30 |
2013-02-27 |
Msd株式会社 |
新規ピペリジン誘導体
|
WO2007018248A1
(ja)
|
2005-08-10 |
2007-02-15 |
Banyu Pharmaceutical Co., Ltd. |
ピリドン化合物
|
EP1921065B1
(en)
|
2005-08-24 |
2010-10-20 |
Banyu Pharmaceutical Co., Ltd. |
Phenylpyridone derivative
|
US20090264426A1
(en)
|
2005-09-07 |
2009-10-22 |
Shunji Sakuraba |
Bicyclic aromatic substituted pyridone derivative
|
BRPI0616463A2
(pt)
|
2005-09-29 |
2011-06-21 |
Merck & Co Inc |
composto, composição farmacêutica, e, uso de um composto
|
CA2625416A1
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
|
JPWO2007049798A1
(ja)
|
2005-10-27 |
2009-04-30 |
萬有製薬株式会社 |
新規ベンゾオキサチイン誘導体
|
MY146564A
(en)
|
2005-11-10 |
2012-08-30 |
Msd Kk |
Aza-substituted spiro derivatives
|
AU2006316100B2
(en)
*
|
2005-11-21 |
2011-12-01 |
Daiichi Sankyo Company, Limited |
Therapeutic agent for skin or skin repair-promoting agent comprising ghrelin, derivative thereof or substance capable of acting on GHS-R1a as active ingredient
|
US8273702B2
(en)
*
|
2006-02-17 |
2012-09-25 |
Wake Forest University Health Sciences |
Wound healing compositions containing keratin biomaterials
|
CU23558A1
(es)
|
2006-02-28 |
2010-07-20 |
Ct Ingenieria Genetica Biotech |
Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
|
CU23592A1
(es)
*
|
2006-02-28 |
2010-11-11 |
Ct Ingenieria Genetica Biotech |
Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
|
WO2007106385A2
(en)
*
|
2006-03-10 |
2007-09-20 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
|
KR20090058553A
(ko)
*
|
2006-09-08 |
2009-06-09 |
바이엘 쉐링 파마 악티엔게젤샤프트 |
18f 표지된 작용제에 대한 화합물 및 방법
|
EP2946778A1
(en)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
AU2007301126A1
(en)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
MX2009003617A
(es)
*
|
2006-10-02 |
2009-04-22 |
Bayer Schering Pharma Ag |
Derivados de silicio para obtencion de imagenes por tomografia de emision de positrones (pet).
|
US20080114055A1
(en)
*
|
2006-11-10 |
2008-05-15 |
Zoltan Laboratories Llc |
Thioxanthone Compounds to Reverse Weight Loss
|
CN101657436A
(zh)
|
2007-02-09 |
2010-02-24 |
特兰齐姆制药公司 |
大环生长素释放肽受体调节剂及其使用方法
|
BRPI0721424A2
(pt)
*
|
2007-03-01 |
2014-03-25 |
Bayer Schering Pharma Ag |
Métodos de radiofluoração
|
US8877717B2
(en)
|
2007-03-12 |
2014-11-04 |
Zadec Aps |
Anti-diabetic extract of rooibos
|
EP2002835A1
(en)
|
2007-06-04 |
2008-12-17 |
GenKyo Tex |
Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Msd株式会社 |
インドールジオン誘導体
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
JP5546451B2
(ja)
|
2007-06-04 |
2014-07-09 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
|
EP2168602A4
(en)
*
|
2007-06-12 |
2014-10-29 |
Inst Pharm & Toxicology Amms |
LINEAR, PEGYLATED, SITE-SPECIFIC SALMON CALCITONIN DERIVATIVES
|
EP2264026A4
(en)
|
2008-03-06 |
2012-03-28 |
Msd Kk |
ALKYLAMINOPYRIDINE DERIVATIVE
|
CA2717384A1
(en)
|
2008-03-28 |
2009-10-01 |
Banyu Pharmaceutical Co., Ltd. |
Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
|
AU2009256157B2
(en)
|
2008-06-04 |
2014-12-18 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
CA2727914A1
(en)
|
2008-06-19 |
2009-12-23 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diaryl ketoxime derivative technical field
|
WO2010009319A2
(en)
|
2008-07-16 |
2010-01-21 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
CA2731358A1
(en)
|
2008-07-30 |
2010-02-04 |
Banyu Pharmaceutical Co., Ltd. |
5/5-or 5/6-membered condensed ring cycloalkylamine derivative
|
EP2165707A1
(en)
|
2008-09-23 |
2010-03-24 |
Genkyo Tex Sa |
Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
|
EP2166010A1
(en)
|
2008-09-23 |
2010-03-24 |
Genkyo Tex Sa |
Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
|
EP2166009A1
(en)
|
2008-09-23 |
2010-03-24 |
Genkyo Tex Sa |
Pyrazolo pyridine derivatives as nadph oxidase inhibitors
|
WO2010047982A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
BRPI0919876A8
(pt)
|
2008-10-30 |
2016-02-10 |
Merck Sharp & Dohme |
Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
|
JP5557845B2
(ja)
|
2008-10-31 |
2014-07-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
|
EP2305679A1
(en)
|
2009-09-28 |
2011-04-06 |
GenKyoTex SA |
Pyrazoline dione derivatives as nadph oxidase inhibitors
|
EP2361911A1
(en)
*
|
2010-02-18 |
2011-08-31 |
GenKyoTex SA |
Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
|
EP2361912A1
(en)
|
2010-02-18 |
2011-08-31 |
GenKyoTex SA |
Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
|
EP2538784B1
(en)
|
2010-02-25 |
2015-09-09 |
Merck Sharp & Dohme Corp. |
Benzimidazole derivatives useful anti-diabetic agents
|
BR112012020377B1
(pt)
*
|
2010-02-26 |
2019-10-08 |
Raqualia Pharma Inc. |
Uso de um composto ou sal farmaceuticamente aceitável do mesmo e embalagem comercial
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
EP2677869B1
(en)
|
2011-02-25 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
CN103547591A
(zh)
*
|
2011-04-21 |
2014-01-29 |
瑟瑞技术公司 |
生长激素释放因子(grf)类似物及其用途
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
CN104470524A
(zh)
*
|
2012-05-25 |
2015-03-25 |
拉夸里亚创药株式会社 |
用于治疗胃酸缺乏症的生长激素释放肽受体激动剂
|
RU2015106909A
(ru)
|
2012-08-02 |
2016-09-27 |
Мерк Шарп И Доум Корп. |
Антидиабетические трициклические соединения
|
NZ707174A
(en)
|
2012-09-27 |
2018-10-26 |
Aratana Therapeutics Inc |
Compositions and methods of use of an inappetance-controlling compound
|
JP6262661B2
(ja)
|
2012-10-24 |
2018-01-17 |
第一三共株式会社 |
筋萎縮性側索硬化症治療剤
|
CA2898482A1
(en)
|
2013-02-22 |
2014-08-28 |
Linda L. Brockunier |
Antidiabetic bicyclic compounds
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
EP3004100B1
(en)
|
2013-05-28 |
2018-06-27 |
RaQualia Pharma Inc. |
Polymorph forms
|
US10011637B2
(en)
|
2013-06-05 |
2018-07-03 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
KR102051433B1
(ko)
*
|
2013-08-27 |
2020-01-08 |
(주)네오팜 |
근육 분화 촉진 및 근육 강화용 조성물 및 외용제
|
US9119832B2
(en)
|
2014-02-05 |
2015-09-01 |
The Regents Of The University Of California |
Methods of treating mild brain injury
|
ES2707124T3
(es)
*
|
2014-08-05 |
2019-04-02 |
Raqualia Pharma Inc |
Derivados de serina como agonistas del receptor de grelina
|
AU2015308350B2
(en)
|
2014-08-29 |
2020-03-05 |
Tes Pharma S.R.L. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
KR20170078612A
(ko)
|
2014-10-31 |
2017-07-07 |
라퀄리아 파마 인코포레이티드 |
그렐린 수용체 효능제로서 테트라히드로피라졸로피리딘 유도체
|
US20170121385A1
(en)
|
2015-10-28 |
2017-05-04 |
Oxeia Biopharmaceuticals, Inc. |
Methods of treating neurodegenerative conditions
|
MX2019004321A
(es)
|
2016-10-14 |
2019-06-12 |
Tes Pharma S R L |
Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
|
EP3479843A1
(en)
|
2017-11-01 |
2019-05-08 |
GenKyoTex Suisse SA |
Use of nox inhibitors for treatment of cancer
|
CN109320515A
(zh)
*
|
2018-11-22 |
2019-02-12 |
常州大学 |
一种Capromorelin手性中间体的不对称合成方法
|
EP3924058A1
(en)
|
2019-02-13 |
2021-12-22 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|